Skip to content
2000
image of Clinical and Medication Factors Associated with Cognitive Decline in Dementia: A Healthcare Database Study

Abstract

Introduction

Dementia is the most common neurodegenerative disease, but the risk factors associated with its progression remain incompletely understood. Identifying clinical and medication-related determinants of cognitive decline may inform patient management and guide treatment strategies.

Materials and Methods

Individuals with dementia who underwent paired Mini-Mental State Examination (MMSE) assessments between 2013 and 2019 were identified from the Taipei Medical University Clinical Research Database. To ensure adequate follow-up, paired assessments were required to be at least 90 days apart, with an actual mean follow-up interval of 21.5 ± 18.0 months. Demographic data, comorbidities, medication prescriptions, and blood biochemistry results were extracted. Generalized estimating equations were applied to evaluate associations between these factors and MMSE changes.

Results

A total of 3,054 individuals with dementia were included (mean age 78.0 ± 9.2 years, 61.1% women). The mean baseline MMSE score was 18.5 ± 6.7 and it declined to 16.0 ± 7.5 at follow-up. Male sex was significantly associated with greater MMSE decline (estimate: -0.920, 95% CI: -1.552 to -0.289, = 0.004). Antidementia medications were significantly associated with less decline in MMSE scores (estimate: 1.245, 95% CI: 0.676 to 1.815, 0.001). In contrast, non-aspirin antiplatelet agent use was associated with a greater decline among men (estimate: -1.346, 95% CI: -2.518 to -0.173, = 0.025).

Discussion

These findings highlighted that both clinical and pharmacological factors influence cognitive decline in dementia. Antidementia medications were linked to slower deterioration, supporting their role in disease management. Conversely, the association of non-aspirin antiplatelet agents with faster decline in men suggested potential adverse effects that warrant further investigation.

Conclusion

In this large real-world cohort, sex and medication use were key determinants of cognitive decline in dementia. Antidementia medications mitigated decline. Notably, only non-aspirin antiplatelet agents, but not aspirin, were associated with greater cognitive decline in men., underscoring the need for personalized treatment approaches.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/car/10.2174/0115672050420540251027112136
2026-01-23
2026-01-29

  • From This Site

    /content/journals/car/10.2174/0115672050420540251027112136
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Khan H.T.A. Addo K.M. Findlay H. Public health challenges and responses to the growing ageing populations. Public Health Chall. 2024 3 3 213 10.1002/puh2.213 40496520
    [Google Scholar]
  2. Lanctôt K.L. Hahn-Pedersen J.H. Eichinger C.S. Freeman C. Clark A. Tarazona L.R.S. Cummings J. Burden of illness in people with alzheimer’s disease: a systematic review of epidemiology, comorbidities and mortality. J. Prev. Alzheimers Dis. 2024 11 1 97 107 10.14283/jpad.2023.61 38230722
    [Google Scholar]
  3. Aparajita A. Jain U. Srivastava P. “Current and emerging drug therapies in Alzheimer’s disease: A pathophysiological Perspective”. Neuroscience 2025 565 499 518 10.1016/j.neuroscience.2024.11.078 39662528
    [Google Scholar]
  4. Takeda S. Rakugi H. Morishita R. Roles of vascular risk factors in the pathogenesis of dementia. Hypertens. Res. 2020 43 3 162 167 10.1038/s41440‑019‑0357‑9 31723253
    [Google Scholar]
  5. McGrath E.R. Beiser A.S. O’Donnell A. Himali J.J. Pase M.P. Satizabal C.L. Seshadri S. Determining vascular risk factors for dementia and dementia risk prediction across mid- to later life. Neurology 2022 99 2 e142 e153 10.1212/WNL.0000000000200521 35584926
    [Google Scholar]
  6. Raulin A.C. Doss S.V. Trottier Z.A. Ikezu T.C. Bu G. Liu C.C. ApoE in Alzheimer’s disease: pathophysiology and therapeutic strategies. Mol. Neurodegener. 2022 17 1 72 10.1186/s13024‑022‑00574‑4 36348357
    [Google Scholar]
  7. Graham A. Livingston G. Purnell L. Huntley J. Mild traumatic brain injuries and future risk of developing alzheimer’s disease: systematic review and meta-analysis. J. Alzheimers Dis. 2022 87 3 969 979 10.3233/JAD‑220069 35491789
    [Google Scholar]
  8. Cho H.S. Huang L.K. Lee Y.T. Chan L. Hong C.T. Suboptimal baseline serum vitamin b12 is associated with cognitive decline in people with alzheimer’s disease undergoing cholinesterase inhibitor treatment. Front. Neurol. 2018 9 325 10.3389/fneur.2018.00325 29867734
    [Google Scholar]
  9. Hong C.H. Falvey C. Harris T.B. Simonsick E.M. Satterfield S. Ferrucci L. Metti A.L. Patel K.V. Yaffe K. Anemia and risk of dementia in older adults. Neurology 2013 81 6 528 533 10.1212/WNL.0b013e31829e701d 23902706
    [Google Scholar]
  10. Wolters F.J. Zonneveld H.I. Licher S. Cremers L.G.M. Ikram M.K. Koudstaal P.J. Vernooij M.W. Ikram M.A. Hemoglobin and anemia in relation to dementia risk and accompanying changes on brain MRI. Neurology 2019 93 9 e917 e926 10.1212/WNL.0000000000008003 31366722
    [Google Scholar]
  11. Tseng W.Y.I. Hsu Y.C. Huang L.K. Hong C.T. Lu Y.H. Chen J.H. Fu C.K. Chan L. Brain age is associated with cognitive outcomes of cholinesterase inhibitor treatment in patients with mild cognitive impairment. J. Alzheimers Dis. 2024 98 3 1095 1106 10.3233/JAD‑231109 38517785
    [Google Scholar]
  12. Farnsworth von Cederwald B. Josefsson M. Wåhlin A. Nyberg L. Karalija N. Association of cardiovascular risk trajectory with cognitive decline and incident dementia. Neurology 2022 98 20 e2013 e2022 10.1212/WNL.0000000000200255 35444051
    [Google Scholar]
  13. Xiong Y. Wong A. Cavalieri M. Schmidt R. Chu W.W.C. Liu X. Wong K.S. Mok V. Prestroke statins, progression of white matter hyperintensities, and cognitive decline in stroke patients with confluent white matter hyperintensities. Neurotherapeutics 2014 11 3 606 611 10.1007/s13311‑014‑0270‑5 24692001
    [Google Scholar]
  14. Alexander P. Visagan S. Jawhar S. Kare A. Issa N. Issa R. Jawhar A. Thomas S. Gorantla V. Antiplatelets and vascular dementia: a systematic review. J. Aging Res. 2022 2022 1 20 10.1155/2022/9780067 36245899
    [Google Scholar]
  15. Ding M. Wennberg A.M. Engström G. Modig K. Use of common cardiovascular disease drugs and risk of dementia: A case–control study in Swedish national register data. Alzheimers Dement. 2025 21 1 14389 10.1002/alz.14389 39555901
    [Google Scholar]
  16. Dou X. Lenzen S. Connelly L.B. Lin R. Generational differences in age-specific dementia prevalence rates. JAMA Netw. Open 2025 8 6 e2513384 e2513384 10.1001/jamanetworkopen.2025.13384 40455442
    [Google Scholar]
  17. Luo H. Koponen M. Roethlein C. Becker C. Bell J.S. Beyene K. Chai Y. Chan A.H.Y. Chui C.S.L. Haenisch B. Hartikainen S. Hsu A.T. Ilomaki J. Kim J.H. Knapp M. Kunkel E. Lai E.C.C. Lau K.K. Lau W.C.Y. Lee H. Liao T.C. Lum T.Y.S. Man K.K.C. Shin J.Y. Tolppanen A.M. Wong G.H.Y. Wong I.C.K. A multinational cohort study of trends in survival following dementia diagnosis. Commun. Med. 2025 5 1 203 10.1038/s43856‑025‑00923‑6 40437158
    [Google Scholar]
  18. Wilkinson T. Ly A. Schnier C. Rannikmäe K. Bush K. Brayne C. Quinn T.J. Sudlow C.L.M. Identifying dementia cases with routinely collected health data: A systematic review. Alzheimers Dement. 2018 14 8 1038 1051 10.1016/j.jalz.2018.02.016 29621480
    [Google Scholar]
  19. Nguyen P.A. Hsu M.H. Chang T.H. Yang H.C. Huang C.W. Liao C.T. Lu C.Y. Hsu J.C. Taipei medical university clinical research database: a collaborative hospital EHR database aligned with international common data standards. BMJ Health Care Inform. 2024 31 1 100890 10.1136/bmjhci‑2023‑100890 38749529
    [Google Scholar]
  20. Hong C.T. Lee H.H. Chung C.C. Chiu W.T. Lee T.Y. Chen D.Y.T. Huang L.K. Hu C.J. Chan L. Poststroke cognitive impairment: a longitudinal follow-up and pre/poststroke mini-mental state examination comparison. Curr. Alzheimer Res. 2022 19 10 716 723 10.2174/1567205019666220802151945 35927922
    [Google Scholar]
  21. Gorelick P.B. Scuteri A. Black S.E. DeCarli C. Greenberg S.M. Iadecola C. Launer L.J. Laurent S. Lopez O.L. Nyenhuis D. Petersen R.C. Schneider J.A. Tzourio C. Arnett D.K. Bennett D.A. Chui H.C. Higashida R.T. Lindquist R. Nilsson P.M. Roman G.C. Sellke F.W. Seshadri S. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. Stroke 2011 42 9 2672 2713 10.1161/STR.0b013e3182299496 21778438
    [Google Scholar]
  22. Nelson A.R. Sweeney M.D. Sagare A.P. Zlokovic B.V. Neurovascular dysfunction and neurodegeneration in dementia and Alzheimer’s disease. Biochim. Biophys. Acta Mol. Basis Dis. 2016 1862 5 887 900 10.1016/j.bbadis.2015.12.016 26705676
    [Google Scholar]
  23. Zotin Z.M.C. Sveikata L. Viswanathan A. Yilmaz P. Cerebral small vessel disease and vascular cognitive impairment: from diagnosis to management. Curr. Opin. Neurol. 2021 34 2 246 257 10.1097/WCO.0000000000000913 33630769
    [Google Scholar]
  24. Hoevenaar-Blom M.P. Richard E. Moll van Charante E.P. van Wanrooij L.L. Busschers W.B. van Dalen J.W. van Gool W.A. Targeting vascular risk factors to reduce dementia incidence in old age. JAMA Neurol. 2021 78 12 1527 1528 10.1001/jamaneurol.2021.3542 34633434
    [Google Scholar]
  25. Douiri A. McKevitt C. Emmett E.S. Rudd A.G. Wolfe C.D.A. Long-term effects of secondary prevention on cognitive function in stroke patients. Circulation 2013 128 12 1341 1348 10.1161/CIRCULATIONAHA.113.002236 23935013
    [Google Scholar]
  26. Wang D.N. Hou X.W. Yang B.W. Lin Y. Shi J.P. Wang N. Quantity of cerebral microbleeds, antiplatelet therapy, and intracerebral hemorrhage outcomes: a systematic review and meta-analysis. J. Stroke Cerebrovasc. Dis. 2015 24 12 2728 2737 10.1016/j.jstrokecerebrovasdis.2015.08.003 26342996
    [Google Scholar]
  27. Kitt K. Murphy R. Clarke A. Reddin C. Ferguson J. Bosch J. Whiteley W. Canavan M. Judge C. O’Donnell M. Antiplatelet therapy and incident cognitive impairment or dementia—a systematic review and meta-analysis of randomised clinical trials. Age Ageing 2023 52 10 afad197 10.1093/ageing/afad197 37897809
    [Google Scholar]
  28. Pan D. Rong X. Li H. Deng Z. Wang J. Liu X. He L. Xu Y. Tang Y. Anti-platelet therapy is associated with lower risk of dementia in patients with cerebral small vessel disease. Front. Aging Neurosci. 2022 14 788407 10.3389/fnagi.2022.788407 35431899
    [Google Scholar]
  29. Amann R. Peskar B.A. Anti-inflammatory effects of aspirin and sodium salicylate. Eur. J. Pharmacol. 2002 447 1 1 9 10.1016/S0014‑2999(02)01828‑9 12106797
    [Google Scholar]
  30. Kinney J.W. Bemiller S.M. Murtishaw A.S. Leisgang A.M. Salazar A.M. Lamb B.T. Inflammation as a central mechanism in Alzheimer’s disease. Alzheimers Dement. 2018 4 1 575 590 10.1016/j.trci.2018.06.014 30406177
    [Google Scholar]
  31. Broe G.A. Grayson D.A. Creasey H.M. Waite L.M. Casey B.J. Bennett H.P. Brooks W.S. Halliday G.M. Anti-inflammatory drugs protect against Alzheimer disease at low doses. Arch. Neurol. 2000 57 11 1586 1591 10.1001/archneur.57.11.1586 11074790
    [Google Scholar]
  32. Imbimbo B.P. Solfrizzi V. Panza F. Are NSAIDs useful to treat Alzheimer’s disease or mild cognitive impairment? Front. Aging Neurosci. 2010 2 19 10.3389/fnagi.2010.00019 20725517
    [Google Scholar]
  33. Lou N Takano T Pei Y Xavier AL Goldman SA Nedergaard Ms Purinergic receptor P2RY12-dependent microglial closure of the injured blood-brain barrier. Proc Natl Acad Sci U S A. 2016 113 4 1074 1079 10.1073/pnas.1520398113
    [Google Scholar]
  34. Paul M. Paul J.W. Hinwood M. Hood R.J. Martin K. Abdolhoseini M. Johnson S.J. Pollack M. Nilsson M. Walker F.R. Clopidogrel administration impairs post-stroke learning and memory recovery in mice. Int. J. Mol. Sci. 2023 24 14 11706 10.3390/ijms241411706 37511466
    [Google Scholar]
  35. Diener H.C. Sacco R.L. Yusuf S. Cotton D. Ôunpuu S. Lawton W.A. Palesch Y. Martin R.H. Albers G.W. Bath P. Bornstein N. Chan B.P.L. Chen S.T. Cunha L. Dahlöf B. De Keyser J. Donnan G.A. Estol C. Gorelick P. Gu V. Hermansson K. Hilbrich L. Kaste M. Lu C. Machnig T. Pais P. Roberts R. Skvortsova V. Teal P. Toni D. VanderMaelen C. Voigt T. Weber M. Yoon B.W. Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. Lancet Neurol. 2008 7 10 875 884 10.1016/S1474‑4422(08)70198‑4 18757238
    [Google Scholar]
  36. Hankey G.J. Eikelboom J.W. Aspirin resistance. Lancet 2006 367 9510 606 617 10.1016/S0140‑6736(06)68040‑9 16488805
    [Google Scholar]
/content/journals/car/10.2174/0115672050420540251027112136
Loading
Clinical and Medication Factors Associated with Cognitive Decline in Dementia: A Healthcare Database Study
Bentham Science Publishers ; https://doi.org/10.2174/0115672050420540251027112136
/content/journals/car/10.2174/0115672050420540251027112136
/content/journals/car/10.2174/0115672050420540251027112136
Loading

Data & Media loading...


  • Article Type:     Research Article
Keywords: mini-mental state examination ; antiplatelet agent ; cognitive decline ; Dementia ; healthcare database ; aspirin

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test